Alexion's Soliris Adds Prescriber Certification In Move From RiskMAP To REMS
This article was originally published in The Pink Sheet Daily
Executive Summary
The REMS for the hemolysis drug seems to be more onerous than the previous RiskMAP, although the company says there are no new safety problems behind the change.